En savoir plus
Ion Channels in Cancer, Volume 92 in the
Current Topics in Membranes series, highlights advances in the field, including chapters on the Interplay of calcium and potassium signals in cell cycle and cancer, Non-conducting functions of ion channels in cancer and neurological disease, Sodium channels and progression of solid tumors, The Elusive Nav1.7: From Pain to Cancer, Signaling Pathways in cancer: Channels Interactome as a novel therapeutic target, Ion channels in cancer drugs resistance, CLIC1: A potential therapeutic target for malignant glioma, Beyond the Building Blocks: Amino Acids as modulators of ion channels and transporters, and Activation of potassium channels unveils tumor vulnerability.
Table des matières
1. Interplay of calcium and potassium signals in cell cycle and cancer2. Non-conducting functions of ion channels in cancer and neurological disease3. Sodium channels and progression of solid tumours4. The Elusive Nav1.7 : From Pain to Cancer5. Signaling Pathways in cancer: Channels Interactome as a novel therapeutic target6. Ion channels in cancer drugs resistance7. CLIC1: A potential therapeutic target for malignant glioma8. Beyond the Building Blocks: Amino Acids as modulators of ion channels and transporters9. Activation of potassium channels unveils tumor vulnerability
A propos de l'auteur
Dr. Gentile obtained his Ph.D. in neurobiology and worked as post-doctoral fellow at the National Institute of Environmental Sciences NIEHS/NIH and at Duke University in which he developed expertise in ion channels. Currently, he is an Assistant professor in the Department of Medicine at the University of Illinois in Chicago. Dr. Gentile’s research focus is on the role of ion channels in cancer biology. His research has brought to light new function of potassium channel in several aspects of cancer including proliferation, senescence, metabolism and metastasis. In collaboration with several clinicians, Dr. Gentile and his team are focusing on developing an anticancer pharmacological approach by targeting potassium channels in breast and ovarian cancer.
